Coastline Trust Co Sells 2,116 Shares of AbbVie Inc. $ABBV

Coastline Trust Co lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 4.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,738 shares of the company’s stock after selling 2,116 shares during the period. AbbVie makes up 1.1% of Coastline Trust Co’s portfolio, making the stock its 23rd biggest position. Coastline Trust Co’s holdings in AbbVie were worth $12,226,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. ACT Advisors LLC. lifted its position in AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after acquiring an additional 41 shares in the last quarter. Willner & Heller LLC increased its holdings in AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after purchasing an additional 43 shares in the last quarter. B.O.S.S. Retirement Advisors LLC raised its stake in shares of AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock valued at $359,000 after purchasing an additional 43 shares during the period. Fielder Capital Group LLC lifted its holdings in shares of AbbVie by 1.7% in the second quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock valued at $637,000 after purchasing an additional 43 shares in the last quarter. Finally, Guardian Wealth Advisors LLC NC boosted its position in shares of AbbVie by 0.4% during the second quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock worth $2,996,000 after buying an additional 43 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Down 0.9%

Shares of NYSE:ABBV traded down $2.26 during trading on Thursday, hitting $259.33. 1,107,928 shares of the company were exchanged, compared to its average volume of 6,428,697. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $269.39. The stock has a market cap of $458.18 billion, a price-to-earnings ratio of 73.22, a P/E/G ratio of 1.19 and a beta of 0.29. The firm has a fifty day moving average price of $257.73 and a two-hundred day moving average price of $234.11.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts predict that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s payout ratio is currently 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Rinvoq produced encouraging long-term vitiligo data. Phase 3 Viti-Up-1 and Viti-Up-2 results showed that facial and total-body repigmentation continued to improve through week 76. Combination treatment with narrowband UV-B phototherapy also produced numerically higher responses, strengthening Rinvoq’s dermatology opportunity. AbbVie Presents Long-Term Rinvoq Data
• Positive Sentiment: Zumilokibart advanced toward Phase 3 development. All three Phase 2 dosing regimens met the primary endpoint in moderate-to-severe atopic dermatitis, significantly improving EASI-75 response rates versus placebo. AbbVie selected the mid-dose regimen, adding a potentially important immunology asset beyond Humira. Zumilokibart Phase 2 Results
• Positive Sentiment: AbbVie’s early metabolic pipeline showed progress. Phase 1 data for long-acting amylin analog ABBV-295 indicated favorable tolerability, meaningful weight reduction and an approximately 11- to 12-day half-life, supporting less-frequent dosing and planned Phase 2 testing. ABBV-295 Phase 1 Data
• Positive Sentiment: The FDA approved Juvmo, a once-daily Parkinson’s disease treatment, expanding AbbVie’s neuroscience portfolio and giving the company exposure to a potentially multibillion-dollar market. AbbVie also formed an AI-development partnership with Valkai, which could improve clinical-development efficiency. AbbVie Juvmo FDA Approval
• Neutral Sentiment: AbbVie will report third-quarter 2026 results before the market opens on October 30. Investors will look for updates on Skyrizi and Rinvoq growth, Humira-related pressure and full-year guidance. AbbVie Third-Quarter Earnings Call
• Negative Sentiment: Despite the strong pipeline news, analysts note that ABBV’s elevated valuation, Humira biosimilar erosion and competitive pressure in immunology could limit upside and increase sensitivity to future clinical or earnings disappointments. AbbVie Buy Hold or Sell Analysis

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings raised shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Piper Sandler lifted their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Guggenheim boosted their price objective on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. increased their target price on shares of AbbVie from $280.00 to $285.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $272.66.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.